The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. 1993

J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
Section of Respiratory Medicine, University of Wales College of Medicine, Llandough Hospital, Penarth, U.K.

The intensity of the host inflammatory response to pulmonary infection with Pseudomonas aeruginosa immediately prior to death was determined in six patients with cystic fibrosis (CF). Plasma concentrations of neutrophil elastase alpha 1-antiproteinase, tumour necrosis factor-alpha (TNF alpha) and serum C-reactive protein (CRP) were increased in the 7 days prior to death (P < 0.05) when compared with a period of clinical stability during the preceding 6 months. An increased inflammatory response was sustained for many weeks prior to death and was associated with poor symptom and lung function responses to apparently appropriate antibiotic treatment.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D003643 Death Irreversible cessation of all bodily functions, manifested by absence of spontaneous breathing and total loss of cardiovascular and cerebral functions. End Of Life,End-Of-Life,Near-Death Experience,Cardiac Death,Determination of Death,Death, Cardiac

Related Publications

J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
August 1999, The European respiratory journal,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
January 1999, Mediators of inflammation,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
December 1997, The Journal of clinical investigation,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
October 1996, The Journal of pediatrics,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
May 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
November 1974, The Journal of infectious diseases,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
October 2006, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
November 2019, Current opinion in pulmonary medicine,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
January 1981, Scandinavian journal of infectious diseases. Supplementum,
J S Elborn, and S M Cordon, and D Parker, and F M Delamere, and D J Shale
November 2022, The clinical respiratory journal,
Copied contents to your clipboard!